Navigation Links
AEterna Zentaris' Partner, Spectrum, Provides Update on Ozarelix in Benign Prostatic Hyperplasia
Date:4/22/2008

QUEBEC CITY, April 22 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ), a global biopharmaceutical company focused on endocrine therapy and oncology, today announced that its partner, Spectrum Pharmaceuticals (NASDAQ: SPPI), released Phase 2b results for ozarelix, a luteinizing hormone-releasing hormone (LHRH) antagonist in benign prostatic hyperplasia (BPH).

Spectrum indicated that ozarelix demonstrated sufficient clinical activity to justify its continued development in BPH. Based on these results, Spectrum is planning to submit a protocol to the FDA for the next study of ozarelix in BPH.

"We are pleased that Spectrum is proceeding with plans for their upcoming study," stated Paul Blake, M.D., Senior Vice President and Chief Medical Officer of AEterna Zentaris. "AEterna Zentaris remains committed about the potential of LHRH antagonists for BPH, particularly for our lead candidate cetrorelix, which has produced robust and consistent findings in Phase 2 trials and is currently being evaluated in three multi-center Phase 3 trials in the United States, Canada and Europe." He said that results from the cetrorelix Phase 3 program are expected in the third quarter of 2009.

About Ozarelix and Partnerships

Ozarelix is an injectable fourth generation LHRH antagonist administered as an intramuscular injection. In August 2004, AEterna Zentaris granted Spectrum Pharmaceuticals an exclusive license to develop and market ozarelix for all potential indications in North America (inc
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. AEterna Zentaris Completes Patient Recruitment for First Phase 3 Efficacy Trial with Cetrorelix in Benign Prostatic Hyperplasia
2. AEterna Zentaris Announces Changes to its Management Team
3. AEterna Zentaris and Paladin Labs Complete Sale and Purchase of Miltefosine Rights
4. Aeterna Zentaris Begins Second Phase 3 Trial of Cetrorelix for Benign Prostatic Hyperplasia
5. Aeterna Zentaris Reports Fourth Quarter and Full-Year 2007 Financial and Operating Results
6. AEterna Zentaris and Paladin Labs Announce Sale and Purchase of Miltefosine Rights
7. AEterna Zentaris Announces the Departure of SVP, Administrative and Legal Affairs
8. Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2007 Financial and Operating Results on March 5, 2008
9. AEterna Zentaris to Present at the Upcoming Roth Capital Partners 20th Annual OC Growth Stock Conference in Dana Point, California
10. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
11. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... developed a technique for controlling the surface tension of ... door to a new generation of reconfigurable electronic circuits, ... fact that the oxide "skin" of the metal ... a surfactant, lowering the surface tension between the metal ... liquid metal alloy of gallium and indium. In base, ...
(Date:9/15/2014)... idea of fibers made of carbon nanotubes is neat, but ... The single-walled carbon nanotubes in new fibers created at Rice ... process designed by chemist Angel Mart and his colleagues. , ... results this month in the journal ACS Nano , ... together into a fiber. , Left to their own devices, ...
(Date:9/15/2014)... (PRWEB) September 15, 2014 Bioptigen ... deep imaging OCT system for the optical device metrology ... EnvisuTM S4410 SDOCT for Contact Lens Metrology ... standard and high complexity contact lens, IOL structures, and ... of a complete contact lens immersed in a hydration ...
(Date:9/15/2014)... Idaho , Sept. 15, 2014  iVinci Health ... only comprehensive Patient Revenue Management system, branded as VisitPay®, ... company also announced the launch of a new extension ... that provides an easy and convenient way for patients ... for balances owed by them and their families. ...
Breaking Biology Technology:Researchers control surface tension to manipulate liquid metals 2Rice rolls 'neat' nanotube fibers 2Rice rolls 'neat' nanotube fibers 3Bioptigen Introduces Deep Imaging OCT System for Contact Lens Metrology 2iVinci Health Raises $5M to Fuel National Expansion, Announces Launch of Personal Finance Portal for Healthcare 2iVinci Health Raises $5M to Fuel National Expansion, Announces Launch of Personal Finance Portal for Healthcare 3
... BEIJING , Feb. 8 /PRNewswire-Asia-FirstCall/ -- China Medical Technologies,Inc. (the "Company") ... participate at the,following investor conferences in March 2010 : , , Investor Conference ... Location, Rodman & Renshaw Annual ... ...
... , Full enrollment occurs five months ahead of ... 8 /PRNewswire-FirstCall/ - Resverlogix Corp. ("Resverlogix" or the "Company") ... Phase 2 clinical study of its lead drug RVX-208. "The ... full 5 months ahead of our original schedule, is a ...
... ... agency, announced today that it has been selected by Invida Group, the leading provider ... communications and public relations program. , ... Salem, MA (Vocus) February 8, 2010 -- LaVoie Group , ...
Cached Biology Technology:China Medical Technologies to Participate Investor Conferences in March 2010 2Resverlogix Completes Patient Recruitment for ASSERT Trial 2Resverlogix Completes Patient Recruitment for ASSERT Trial 3Resverlogix Completes Patient Recruitment for ASSERT Trial 4Invida Selects LaVoie Group as Public Relations Agency of Record 2Invida Selects LaVoie Group as Public Relations Agency of Record 3
(Date:9/15/2014)... is a vital source of energy for both plants ... its way into the cell could lead to the ... increase in the amount of fruits and vegetables farmers ... uncovered one of these "pathways" into the cell by ... a strand of spider silk. , To determine the ...
(Date:9/15/2014)... issue of the journal Science comes out, ... Montana and even the Netherlands, thanks to the type ... norm in these connected times. Yes, the research was ... in biology, medicine, biotechnology and agriculture. It could save ... that one, that one knew another one, and brilliant ...
(Date:9/15/2014)... reef ecologists fears that reef biodiversity may not provide ... once thought. , In an international study published today, ... for Coral Reef Studies (Coral CoE) says we need ... reef ecosystems. , In coral reefs, just as in ... the ecosystem safe and functioning. , Professor Bellwood ...
Breaking Biology News(10 mins):X-rays unlock a protein's SWEET side 2X-rays unlock a protein's SWEET side 3Collaboration drives achievement in protein structure research 2Specialized species critical for reefs 2
... of infection in some hospital wards varies dramatically according ... A University of Leeds-led team studied airflow in a ... two rows of up to 30 bedsby using tracer ... found ventilation in the ward was generally good when ...
... CITY, Calif. , April 16, 2013   DigitalPersona, ... solutions, today announced that Papa John,s restaurants in ... fingerprint biometrics to speed and secure employees, and managers, ... in northern China are using ...
... April 16, 2013 Studies have shown that about ... (HIV) have an elevated resting energy expenditure (REE). Their ... body temperature, and breathing. Most studies have been conducted ... small sample sizes. A team of researchers has sought ...
Cached Biology News:Energy efficiency could increase infection risks in hospital wards 2Energy efficiency could increase infection risks in hospital wards 3Papa John's Restaurants in China Speed and Secure Workflow with DigitalPersona Fingerprint Biometrics 2Women with HIV shown to have elevated resting energy expenditure 2
These disposable button tethers are designed for rat infusion studies lasting more than 2 weeks. After one to two weeks the subcutaneous tissue will grow into the Dacron mesh, making the sutures irre...
Bethyl Laboratories Epitope Retrieval Buffer-Reduced pH will unmask antigenic sites from formaldehyde fixation and allow for subsequent immunostaining. Shelf-Life: 1 year from date of receipt...
Mycoplasma and virus tested...
Mycoplasma and virus tested...
Biology Products: